Stock ZLAB ZAI LAB LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Zai Lab Limited Stock

Equities

ZLAB

US98887Q1040

Pharmaceuticals

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-23 pm EDT 		5-day change 1st Jan Change
19.06 USD -5.46% Intraday chart for Zai Lab Limited -8.59% -30.26%
May. 22 Zai Lab Doses First Patient in a Phase 2 Clinical Trial of Plaque Psoriasis Treatment; Shares Rise MT
May. 20 Chinese Regulator Approves Zai Lab’s New Drug Application for Bacterial Pneumonia Drug MT

Financials (USD)

Sales 2024 * 389M Sales 2025 * 617M Capitalization 2B
Net income 2024 * -277M Net income 2025 * -130M EV / Sales 2024 * 3.75 x
Net cash position 2024 * 538M Net cash position 2025 * 275M EV / Sales 2025 * 2.79 x
P/E ratio 2024 *
-6.93 x
P/E ratio 2025 *
-17.8 x
Employees 2,175
Yield 2024 *
-
Yield 2025 *
1.05%
Free-Float 9.91%
More Fundamentals * Assessed data

Chart Zai Lab Limited

Dynamic Chart

Latest news about Zai Lab Limited

Zai Lab Doses First Patient in a Phase 2 Clinical Trial of Plaque Psoriasis Treatment; Shares Rise MT
Chinese Regulator Approves Zai Lab’s New Drug Application for Bacterial Pneumonia Drug MT
Zai Lab, Innoviva Subsidiary Receive China Approval for Hospital Infection Treatment MT
Asian Equities Traded in the US as American Depositary Receipts Ease in Thursday Trading MT
Zai Lab's Supplemental Application for Autoimmune Disease Treatment Accepted by China Regulator MT
Zai Lab Announces Acceptance of Supplemental Biologics License Application with Priority Review for Efgartigimod Alfa Injection (Subcutaneous Injection) in Chronic Inflammatory Demyelinating Polyneuropathy in China CI
Asian Equities Traded in the US as American Depositary Receipts Begin Week Higher MT
Zai Lab Says China Approves New Drug Application for Lung Cancer Treatment Augtyro MT
Zai Lab's Cancer Drug Gets NDA Approval in China MT
Zai Lab's Shares Rise After Q1 Beat MT
Asian Equities Traded in the US as American Depositary Receipts Trend Lower Thursday MT
Top Premarket Gainers MT
Transcript : Zai Lab Limited, Q1 2024 Earnings Call, May 09, 2024
Zai Lab Q1 Loss Widens Despite Higher Revenue MT
Tech Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Slightly Higher in Monday Trading MT
More news

Latest transcript on Zai Lab Limited

Logo Zai Lab Limited
Zai Lab Limited, Q1 2024 Earnings Call, May 09, 2024
More transcripts

Analyst Recommendations on Zai Lab Limited

Zai Lab CEO, Others 'Do Not Anticipate' Selling Company Shares in Remainder of 2024 MT
Zai Lab Grants Share Options, Restricted Share Units to Eligible Personnel MT
Morgan Stanley Starts Coverage on Zai Lab with Overweight Rating, $47.50 Price Target MT
Citigroup Adjusts Price Target on Zai Lab to $128 From $130, Maintains Buy Rating MT
Goldman Sachs Lowers Price Target on Zai Lab to $73.34 From $82.47, Maintains Buy Rating MT
More recommendations

Press releases Zai Lab Limited

Zai Lab Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque Psoriasis BU
Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China AQ
Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China BU
Zai Lab Announces Participation in May and June Investor Conferences BU
Zai Lab Announces Acceptance of Supplemental Biologics License Application with Priority Review for Efgartigimod Alfa Injection (Subcutaneous Injection) in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China BU
More press releases

News in other languages on Zai Lab Limited

Hong Kong se convierte en el principal mercado para las cotizaciones chinas, según HKEX -- Market Talk
Tweede kwartaal Argen-x in teken lancering Vyvgart
Brussel fors hoger van start na Fed-rally op Wall Street
Argenx boekt eerste omzet met Vyvgart
EN DIRECTO DESDE LOS MERCADOS: Stellantis, Wendel, Soitec, Umanis, Tod's, Deutsche Telekom, Oracle, Rivian...
More news

Quotes and Performance

1 day-5.46%
1 week-8.59%
Current month+20.63%
1 month+27.15%
3 months-5.08%
6 months-30.67%
Current year-30.26%
More quotes

Highs and lows

1 week
18.58
Extreme 18.575
21.07
1 month
15.05
Extreme 15.05
22.35
Current year
13.48
Extreme 13.48
27.87
1 year
13.48
Extreme 13.48
37.92
3 years
13.48
Extreme 13.48
181.92
5 years
13.48
Extreme 13.48
193.54
10 years
13.48
Extreme 13.48
193.54
More quotes

Managers and Directors - Zai Lab Limited

Managers TitleAgeSince
Ying Du CEO
 Chief Executive Officer 59 14-03-31
Ya jing Chen DFI
 Director of Finance/CFO 56 21-08-31
Joshua Smiley PSD
 President 54 22-07-31
Members of the board TitleAgeSince
John Diekman BRD
 Director/Board Member 81 16-12-31
Peter Wirth BRD
 Director/Board Member 73 16-12-31
Lonnie Moulder BRD
 Director/Board Member 66 18-12-31
More insiders

ETFs positioned on Zai Lab Limited

Name Weight AuM 1st Jan change Investor Rating
LONCAR CHINA BIOPHARMA ETF - DISTRIBUTING - USD ETF Loncar China BioPharma ETF - Distributing - USD
1.29% 4 M€ -27.92%
KRANESHARES MSCI ALL CHINA HEALTH CARE INDEX UCITS ETF - USD ETF KraneShares MSCI All China Health Care Index UCITS ETF - USD
1.04% 2 M€ -16.67% -
FIRST TRUST CHINDIA ETF - USD ETF First Trust Chindia ETF - USD
0.75% 96 M€ -.--% -
LEVERAGE SHARES -3X SHORT BIOTECHNOLOGY ETP SECURITIES - USD ETF Leverage Shares -3x Short Biotechnology ETP Securities - USD
0.27% 0 M€ 0.00% -
More ETFs positioned on Zai Lab Limited

Quotes

Date Price Change Volume
24-05-23 19.06 -5.46% 582,095
24-05-22 20.16 +0.75% 334,296
24-05-21 20.01 -3.98% 294,198
24-05-20 20.84 +7.42% 825,927
24-05-17 19.4 -2.66% 463,667

Delayed Quote Nasdaq, May 23, 2024 at 04:00 pm EDT

More quotes

Company Profile

Zai Lab Ltd is a holding company mainly engaged in the biopharmaceutical field. The Company is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including oncology, autoimmune and infectious diseases fields. The Company has a broad pipeline of proprietary drug candidates that range from discovery stage to late-stage clinical programs. These include Niraparib (ZL-2306), ZL-2103, ZL-1101 and others.
Sector
Pharmaceuticals
Calendar
2024-06-05 - Jefferies Global Healthcare Conference
More about the company

Income Statement Evolution

More financial data

Ratings for Zai Lab Limited

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
20.16 USD
Average target price
51.37 USD
Spread / Average Target
+154.82%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

1st Jan change Capi.
ZAI LAB LIMITED Stock Zai Lab Limited
-30.26% 2B
CSL LIMITED Stock CSL Limited
-1.62% 89.22B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+1.32% 40.49B
BIOGEN INC. Stock Biogen Inc.
-15.73% 32.79B
UCB Stock UCB
+64.13% 26.23B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-21.28% 14.52B
INCYTE CORPORATION Stock Incyte Corporation
-8.50% 13.09B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-44.07% 11.6B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-13.06% 11.5B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+4.94% 8.82B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. ZLAB Stock